SEC Company Response from Nuo Therapeutics, Inc. (AURX) (CIK 0001091596) (AURX) — Jan 9, 2017
Nuo Therapeutics, Inc. (AURX) (CIK 0001091596)
Date: Jan. 9, 2017 · CIK: 0001091596 · Accession: 0001144204-17-001263
AI Filing Summary & Sentiment
File numbers found in text: 333-214748
Letter
Re: Nuo Therapeutics, Inc.
[Letterhead of Nuo Therapeutics, Inc.]
January 9, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Registration Statement on Form S-1/A
Filed December 23, 2016
File No. 333-214748
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration Statement referred to above be accelerated so that it will be declared effective at 9:00 AM on January 11, 2017, or as soon thereafter as is practicable.
Very truly yours,
Nuo Therapeutics, Inc.
Show Raw Text
CORRESP
1
filename1.htm
[Letterhead of Nuo Therapeutics, Inc.]
January 9, 2017
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Nuo Therapeutics, Inc.
Registration Statement on Form S-1/A
Filed December 23, 2016
File No. 333-214748
Ladies and Gentlemen:
In accordance with
Rule 461 under the Securities Act of 1933, as amended, the undersigned respectfully requests that the effective date for the Registration
Statement referred to above be accelerated so that it will be declared effective at 9:00 AM on January 11, 2017, or as soon thereafter
as is practicable.
Very truly yours,
Nuo Therapeutics, Inc.
By:
/s/ David E. Jorden
Name:
David E. Jorden
Title:
Chief Executive Officer and Chief Financial Officer